Caption: Syntekabio and Arctoris join their forces in the fight against COVID-19. Together, they substantially accelerate drug discovery by combining their leading technologies: Syntekabio’s in silico modeling simulation and Arctoris’ fully-automated in vitro validation.

Oxford, UK – 14 September 2020 Life Science Newswire – Arctoris, the creator of the world’s first fully automated drug discovery platform, has signed a Memorandum of Understanding with listed Korean company Syntekabio, Inc. to collaborate on drug discovery efforts. The first project under the agreement sees the two companies work together to assess small molecule therapeutics for COVID-19.

The MoU brings together two highly complementary technologies: Syntekabio is a leading AI-driven drug discovery company that uses machine learning and supercomputing to discover new drugs, and Arctoris is a British technology company that has developed a fully automated drug discovery platform enabling rapid generation of high-quality drug discovery data. Syntekabio will use Arctoris’ unique technology platform for biochemical and cell-based experiments including target-based assays and viability assessments.

Access to the Arctoris platform enables the company’s clients and partners to conduct their drug discovery processes in full automation. Available services include dataset generation for AI model training and validation, hit-to-lead, lead optimisation and candidate selection.

Under the terms of the MoU, Syntekabio and Arctoris work together to identify and screen a series of potential candidate molecules for COVID-19 treatment, not only saving development time, but also ensuring a greater degree of confidence in the experimental results.

Martin-Immanuel Bittner MD DPhil, CEO of Arctoris said:
"This partnership highlights the utility and capability of the Arctoris approach to drug discovery. Thanks to our robotic technology platform we can significantly accelerate the identification of candidates for COVID-19 treatment. By combining the novel technologies developed by Arctoris and Syntekabio, we aim to develop potential new treatments faster - for COVID-19 and beyond."

Sunil Youn MD, Director of Business Development of Syntekabio, adds:
"Syntekabio is a leader in AI-driven drug discovery. We are pleased to collaborate with Arctoris, enabling us to rapidly validate our in silico predictions. Together, we can reach the next drug discovery milestones faster."

The MoU with Syntekabio is the latest in a series of partnerships formed by Arctoris this year, which includes publicly announced partnerships with Insilico Medicine and Molecule.

Financial details were not disclosed.

For more information, please visit https://www.arctoris.com or follow us on LinkedIn.